Former Facebook CEO (ANZ) Stephen Scheeler Announced as Keynote Speaker for Better Outcomes

SYDNEY, AU, June 18, 2024 – (ACN Newswire) – AlayaCare, a leading Home and Residential Care software provider, today announces Stephen Scheeler – former CEO of Facebook ANZ, renowned business leader, and digital innovation expert – as the keynote speaker at Better Outcomes 2024. Better Outcomes is AlayaCare’s flagship user conference that will be held on 3 September in Sydney.

Scheeler brings vast experience as a leader who drove Facebook’s unprecedented rise in Australia and New Zealand, and as a strategic advisor to major corporations on digital disruption and the future of technology. Scheeler’s insights, demonstrated by his contributions to TEDx, The Wall Street Journal, Forbes, and The Australian Financial Review, will provide valuable insights to attendees looking to prioritise innovation and transformation in the digital age.

Following a successful year in 2023, Better Outcomes returns in 2024 to provide professionals in the aged and disability industry with an unparalleled opportunity to learn from leading industry experts about the latest advancements in healthcare technology. Better Outcomes melds innovation and practical application, empowering attendees to implement leading practices, forge lasting industry relationships, and be at the forefront of technological advancement in their sector.

“We are thrilled to have Stephen Scheeler speaking at Better Outcomes this year,” says Annette Hili, General Manager AlayaCare ANZ. “In a sector that is constantly evolving, Stephen’s insights into technological transformation and innovation will be incredibly valuable to our attendees. We look forward to the inspiration and practical knowledge he will share, helping our community achieve better outcomes in care delivery.”

Learn more about Better Outcomes and register here: https://alayacare.com/en-au/better-outcomes-2024/

For more information, please contact:
Bel Bennett
Director Marketing ANZ
bel.bennett@alayacare.com

About AlayaCare

AlayaCareis a leading technology provider for the aged and disability sectors, revolutionising care delivery through AI-based software. Our platform, supported by a dedicated local team, streamlines operations, offers real-time data insights, enhances personalised care, and enables seamless customisation without vendor support. With a $50 million annual investment in research and AI-driven solutions, AlayaCare is at the forefront of driving innovation in the care community. Visit alayacare.com.auto learn about our transformative, world-class technology that’s tailor-made for aged and disability providers.

SOURCE: AlayaCare



Copyright 2024 ACN Newswire. All rights reserved. http://www.acnnewswire.com

AlayaCare Residential Launches Financial Management for Retirement Living

SYDNEY, AU, June 17, 2024 – (ACN Newswire) – AlayaCare Residential, an All-In-One cloud solution that’s reimagining care across Australia and New Zealand, today announces the launch of Financial Management for Retirement Living. This new feature, an update to AlayaCare Residential’s existing Financial Management component, cements AlayaCare Residential as an All-In-One cloud solution facilitating an end-to-end continuum of care.

This significant milestone enables organisations to track clients’ finances throughout their care journey. Bridging the gap between Retirement Living and Residential Aged Care, residents and staff can now refer to a single client record for all facets of residential care, ensuring a smooth transition between care environments.

Arif Mohamed, Vice President of Residential at AlayaCare, emphasises this new feature’s impact for customers, stating, “AlayaCare Residential supports businesses as they scale, and helps teams deliver more comprehensive and personalised care. Offering an improved financial management experience enables our customers to experience a holistic approach to residential care management.”

Financial Management for Retirement Living is a stand-alone feature that seamlessly integrates with the AlayaCare Residential software. Built in close collaboration with industry clinicians, AlayaCare Residential is designed to support the daily delivery of outstanding clinical care. This powerful software enables a unique configuration of workflows and documents to suit each organisation’s needs.

For more information about AlayaCare Residential’s All-In-One cloud solution and its innovative features, please visit www.alayacare.com.au.

For more information
AlayaCare Press Contact:
Bel Bennett
Director Marketing ANZ
bel.bennett@alayacare.com

About AlayaCare

AlayaCare is a leading technology provider for the aged and disability sectors that’s revolutionising care delivery. The platform, supported by a dedicated local team, streamlines operations, offers real-time data insights, enhances personalised care, and enables seamless customisation without vendor support. Visit alayacare.com.au to learn about our transformative, world-class technology that’s tailor-made for aged and disability providers.

SOURCE: AlayaCare



Copyright 2024 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Homegrown Robobarista Ella Achieves Highest Daily Record of 400 Cups of Coffee Sold at Sengkang General Hospital, Paving Way for Additional Waves of Expansion in the Healthcare Sector

  • Ella, Singapore’s AI-powered Robobarista, has integrated into the healthcare ecosystem with major healthcare facilities namely, Sengkang General Hospital (SKH), Mount Elizabeth Hospital and Alexandra Hospital as its third location.
  • While it was originally developed for the retail industry, Ella’s success in the healthcare industry has proven its versatility in carving out a niche to serve specialised sectors in need of on-demand beverages 24/7.
  • In 2024, Ella is poised for expansion to more SingHealth hospitals and facilities locally, as it continues to serve barista-grade coffee at precision and speed.

SINGAPORE, June 12, 2024 – (ACN Newswire) – Ella by Crown Digital, Singapore’s first fully-autonomous, AI-led robot barista, has garnered significant acclaim at Sengkang General Hospital (SKH) and Mount Elizabeth Hospital. Her remarkable success in serving healthcare professionals and visitors with precision and efficiency has propelled her expansion into additional healthcare facilities across the nation. Alexandra Hospital is the latest to benefit from Ella’s presence, marking a milestone in her service journey nationwide.

Following Ella’s resounding success in her deployment at SKH, where she not only met but exceeded expectations by achieving a record daily average of 400 cups of coffee, her adaptability and relevance in healthcare settings became undeniable. Seamlessly integrating into the hospital environment, Ella continues to bring convenience and comfort to all through her consistent, efficient and contactless approach to serve high volumes of coffee at precision and speed. Now, with her recent launch at Alexandra Hospital, Ella has elicited positive feedback from healthcare providers, patients, and visitors alike within her first week.

“We are excited to launch Ella in Alexandra Hospital, extending the comfort and convenience of a great cuppa she’s brought to Sengkang General Hospital since October last year. By delivering high-quality barista-grade coffee to our healthcare heroes, patients, and caregivers, Ella embodies our commitment to unparalleled efficiency and reliability. Occupying just four-square-metres, Ella can be easily deployed across various locations while seamlessly managing payments, orders, production, and pick-up through Crown Digital’s technology stack. As we forge ahead, embracing innovation and robotics solutions, our success at SKH drives our continued expansion, commitment and leadership in this space,” said Keith Tan, CEO and Founder of Crown Digital.

Ella’s success underscores the consistent demand in healthcare settings for her precision, speed, and contactless efficiency in serving best tasting coffee ensuring unparalleled convenience and satisfaction to all stakeholders. Originally designed for the retail sector, Ella’s success in healthcare has solidified her position and expanded her reach to serve more consumers. Since her inception in 2018, Ella has delighted coffee enthusiasts locally and globally with artisanal, barista-grade coffee crafted from specially-curated Italian Buscaglione beans, ensuring consistent quality and precision. Capable of serving over 200 cups in an hour, Ella offers a swift coffee fix, significantly reducing wait times during peak periods.

Charity Wai, Chief Operating Officer of Sengkang General Hospital added, “Ella has earned a popular following in Sengkang General Hospital as visitors and staff alike appreciate the barista-grade coffee served with consistency, precision and speed. Having the first fully-autonomous AI-led robot barista aligns well with SKH’s vision also in using robotics and digitalisation to ensure we deliver quality care consistently and efficiently!  It’s great to see our visitors, patients and hospital staff able to access a good cup of coffee around the clock.”

“Ella was a lifesaver during my husband’s 6-week stay at Mount Elizabeth Hospital. On the many occasions that I stayed over with my husband, waking up to a nice fresh cup of coffee was essential. Subscribing to the pre-order service ensured I was able to have a quality cup of coffee anytime of the day which I appreciated the most. The commute between home, office and hospital became such a routine that Ella was the only comfort that kept my spirits up. It’s incredible how technology can bring such comfort, turning every stressful situation into a positive moment. Ella’s more than just a robot barista, but a beacon of cheer in a place where people are most vulnerable,” shared Crystal Bok, whose husband was warded at Mount Elizabeth Hospital.

Following Crown Digital’s success with three major healthcare providers in Singapore — SingHealth, National University Health System, and Parkway Health — Ella is poised for wider adoption in 2024. 

About Crown Digital

Full-stack start-up Crown Digital began with the goal of delivering a contactless coffee experience gourmet experience to the world’s growing community of grab-and-go commuters. Its creation, ELLA, the one of world’s first successful robot barista, humanised technology and demonstrated the potential of robotics and AI to re-invent the commuter lifestyle experience and re-energize urban retail. As ELLA deploys across major Asian transit hubs and retail locations, and now into the European Market, Crown Digital brings its expertise and insights to find new ways to create social value through robotics. The company strives to re-imagine and re-invent consumer-facing robotics to become the leading inventor, operator, and distributor of future-ready solutions.

For media enquiries, please contact ella@preciouscomms.com.



Copyright 2024 ACN Newswire. All rights reserved. http://www.acnnewswire.com

DC Healthcare’s Approve All Resolutions in AGM

KUALA LUMPUR, June 12, 2024 – (ACN Newswire) – DC Healthcare Holdings Berhad (“DC Healthcare” or the “Group”), an aesthetic medical services provider specialising in the provision of non-invasive and minimally invasive procedures, is pleased to announce the successful completion of its Second Annual General Meeting (“AGM”) held virtually on June 11, 2024. The AGM was conducted through Remote Participation and Voting facilities, allowing shareholders to actively participate and cast their votes on key resolutions.

Dr. Chong Tze Sheng, Managing Director of DC Healthcare
Dr. Chong Tze Sheng, Managing Director of DC Healthcare

During the AGM, shareholders approved all the resolutions including the adoption of the Audited Financial Statements for the year ended December 31, 2023. Key resolutions passed also involved the re-election of directors, ratification of directors’ fees, and the re-appointment of Messrs. Moore Stephens Associates PLT as the Company’s auditors.

Dr. Chong Tze Sheng, Managing Director of DC Healthcare expressed his gratitude to the shareholders, said, “We are incredibly thankful for the continued support and trust our shareholders place in us. This AGM not only reflects our commitment to transparency and robust corporate governance but also sets the path for our strategic initiatives aimed at enhancing service excellence and expanding our market presence. As we move forward, we remain dedicated to leveraging our strengths to drive sustainable growth and deliver value to all our stakeholders.”

Looking ahead, DC Healthcare is dedicated to strengthening its position in the medical aesthetics sector by implementing focused business strategies. These include expanding our clinics across Southern and Northern Malaysia, recruiting highly skilled and experienced staff, and continuously upgrading medical equipment with the latest technology to support growth and improve service quality. The Group remains optimistic about its future, bolstered by competitive advantages that are well-suited to drive sustainable growth in a dynamic market.

DC Healthcare Holdings Berhad https://dchealthcareholdings.com/ 



Copyright 2024 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Southeast Asia’s Most Advanced Luxury Postpartum Centre Re’Joy Suites Opens in Singapore

SINGAPORE, June 10, 2024 – (ACN Newswire) – Re’Joy Suites (“Re’Joy”), Southeast Asia’s most advanced postpartum centre providing advanced care for mothers immediately after childbirth with a blend of Traditional Chinese Medicine (“TCM”) and modern healthcare in a luxury spa and hotel setting in Singapore, has been unveiled by the Joyre Group (“Joyre” or the “Group”).

With a built-up area of over 30,000 sqft (2787 sqm) and 30 rooms, the centre offers several world firsts dedicated to providing the highest level of ‘confinement’ care that resonates TCM philosophy with modern innovation such as acupuncture and moxibustion administered by robots and enabled with artificial intelligence.

Occupying three four-storey buildings at 3 Croucher Road, Re’Joy is within a 20-minutes’ drive to eight local hospitals, ensuring that mother and child can receive specialised care immediately after delivery.

New mums often experience post-partum symptoms during the first few weeks after childbirth.  These ‘baby blues’ can include feelings of anxiety and mood swings, crying spells and sleep disorders, which can sometimes result in depression.

Asian mothers have for millennia practised ‘confinement’ to recuperate, often with a diet that includes TCM herbs and prescriptions. These traditions have persisted even with the advance of modern healthcare, leading to a gap in the market – identified by Joy’Re – to combine East and West in a bespoke setting. Mothers can recover “sitting in” or “lying in”, depending on different cultures and ethnic origins, between 21 to 100 days.

The Joy’Re facility also offers an all-round wellness experience, including tailored yoga sessions for postpartum recovery, hyperbaric oxygen therapy, postnatal and lactation massages, and sound bathing. Mothers can also enjoy classes for yoga, dance, and water exercise, and participate in social activities such as arts & crafts, mahjong, knitting and karaoke.

Each suite is meticulously designed with functionality, ensuring every mother’s comfort without compromising on style. Each room is fitted with a customised bathtub designed for TCM herbal medical post-natal baths and pull-out beds for guests.

Babies are cared for in dedicated nursery rooms with an oxygen delivery system, while parents can access a 24/7 live video feed from the suites. Additional services include baby massages, an immune therapy program as well as DNA and gut health testing for parents to better understand their child’s health and genetic make up.

Re’Joy offers three tiers of packages – Deluxe, Premium, and Platinum packages. Packages begin with a minimum stay of 28 days with customers having the flexibility to choose a stay period that fits their personal and medical needs.

Deluxe package customers will enjoy the comfort and style of Re’Joy’s Deluxe suites, each spanning an impressive 301 sqft (28 sqm), while the Premium or Platinum customers will stay in the 398 sqft (37 sqm) Premium suites, which feature additional amenities and space. The Platinum package offers the most comprehensive array of services and luxuries, ensuring the highest level of care and convenience.

Mothers will also enjoy up to five meals per day, prepared by in-house chefs. The meals are carefully curated by nutritionists and TCM practitioners, ensuring meals are delicious while supporting the recovery needs of postpartum mothers.

Re’Joy Suites marks Joyre Group’s inaugural venture into the postpartum confinement centre industry, building upon Joyre’s 19 years of expertise in providing premium spa treatments combined with TCM principles. The Group plans to expand Re’Joy’s portfolio of services to cover pre-natal care, as well as drop-off child care services.

Founded in 2005, Joyre is Singapore’s largest health, beauty and wellness Group with 14 brands and over 40 outlets islandwide offering spa services, medical aesthetic clinics, as well as healthcare and skincare product manufacturing and distribution. The Group has over 600 staff worldwide, 500 of which are in Singapore and the rest spread across Malaysia, Indonesia, China, the U.S., and Japan. 

Ms Queenie Yang Rong, the founder of Joyre Group and Re’Joy Suites said “Joyre Group is excited to offer Re’Joy Suites as a fresh yet carefully curated luxury option for Asian mothers. Our dedicated facility is ready to provide the highest level of service, relieving our customers of the heavy demands of newborn care and allowing them to embrace the joys of their new family.”  

“We intend to use Singapore as a springboard for our brand of postnatal care by leveraging our deep-rooted expertise in spa and wellness services to offer holistic healthcare and to set a new standard in the confinement centre industry.”

For more information about Re’Joy Suites, please visit https://rejoy.sg/about-us/ or contact

Re’Joy Suites
3 Croucher Road
Singapore 359566

Email: info@rejoy.sg
Facebook: rejoysuites
Instagram: rejoysuites
Website: www.rejoy.sg

About Re’Joy Suites

Re’Joy Suites is a luxury postpartum centre that combines the wisdom of the East with modern medical knowledge to provide personalised postnatal care through a holistic regime approach for mothers and their babies. Re’Joy Suites Confinement Center is operated by a team of dedicated healthcare and postpartum care professionals and offers the full suite of services including the care of medical doctors, trained nurses, lactation specialists, TCM physicians, specially curated meals, postpartum body treatments and aesthetic treatments.

About Joyre Group

Joyre Group is an internationally trusted and trailblazing brand in holistic well-being built on the foundation of science and TCM, leveraging highly professional services, quality products and technological innovations to meet the lifetime needs of a wide spectrum of consumers.  We are the pioneer and leader in integrating Traditional Chinese Medicine with modern spa treatments and beauty aesthetics services to deliver total wellness to all while adopting a suite of Advanced Biomedical Technology. At Joyre, we believe beauty is cultivated from the inside to the outside. Our personalised treatments are designed to match everyone’s body constitution and lifestyle to bring about a sense of balance and total wellness. Our finesse as an institution has garnered us several awards over the years.



Copyright 2024 ACN Newswire. All rights reserved. http://www.acnnewswire.com

HighTide Therapeutics Presents Analyses of Phase 2a MASH Study at the 2024 International Liver Congress, Reinforcing and Further Characterizing the Efficacy and Safety of Berberine Ursodeoxcyholate (HTD1801)

ROCKVILLE, MD and SHENZHEN, CHINA, June 5, 2024 – (ACN Newswire) – HighTide Therapeutics, Inc. (HKEX: 2511), a clinical stage biopharmaceutical company specializing in the development of multi-targeted therapies for chronic liver and metabolic diseases, announced that it will make multiple presentations at the European Association for the Study of the Liver (EASL) Congress, taking place from June 5-8, 2024 in Milan, Italy. The presentations include post-hoc analyses of the Phase 2a clinical study of berberine ursodeoxcyholate (HTD1801), a gut-liver anti-inflammatory metabolic modulator, in patients with metabolic dysfunction-associated steatohepatitis (MASH) and comorbid type 2 diabetes mellitus (T2DM) (NCT03656744).

“These data provide additional insight on the potential benefits of HTD1801, a novel, multifunctional therapy being developed for the treatment of patients with MASH and T2DM. The ongoing multi-regional Phase 2b study (CENTRICITY, NCT05623189), now fully enrolled, evaluates the histologic benefit of HTD1801 in this same patient population. We look forward to the results of CENTRICITY which is on track to read out in the first half of 2025,” said Dr. Leigh MacConell, Chief Development Officer of HighTide.

“Efficacy of Berberine Ursodeoxycholate (HTD1801) Compared to Ongoing Use of GLP-1 Receptor Agonists in Patients with MASH and T2DM” (Abstract SAT-227, Poster Presented June 8)

About the Abstract: As GLP-1 Receptor Agonists (GLP-1RAs) are prominently used in patients with T2DM and gaining attention as a potential treatment for MASH, this post-hoc comparative efficacy analysis evaluated ongoing GLP-1RA use compared to newly initiated HTD1801 treatment. This analysis suggests that HTD1801 provides greater benefit across multiple cardiometabolic endpoints compared to ongoing GLP-1RA use. These findings are important as they suggest that patients with MASH and T2DM, on concomitant GLP-1RA treatment, could achieve additional benefit with HTD1801 in terms of further glucose and lipid lowering as well as weight loss.

“Berberine Ursodeoxycholate (HTD1801) Provides a Unique Therapeutic Approach for Patients with Metabolic Liver Disease and Severe Insulin Resistance” (Abstract SAT-225, Poster Presented June 8)

About the Abstract: Insulin resistance is a significant risk factor for T2DM, obesity and MASH. HTD1801 enhances the utilization of glucose and fats through activation of AMP-activated protein kinase (AMPK), thereby improving insulin sensitivity. As HTD1801 is under development as a treatment for patients with MASH and T2DM, the objective of this post-hoc analysis was to evaluate the effects of HTD1801 based on degree of insulin resistance. These data demonstrate that HTD1801 can alleviate the metabolic inhibitory effects caused by hyperinsulinemia, leading to even greater metabolic benefits in patients with MASH and more severe insulin resistance and therefore may offer a unique therapeutic approach for individuals with MASH and T2DM.

“Time Course of Onset, Incidence, and Prevalence of Gastrointestinal Adverse Events with HTD1801 (Berberine Ursodeoxycholate) in Patients with MASH and T2DM” (Abstract SAT-243, Poster Presented June 8)

About the Abstract: The most commonly occurring adverse events (AEs) in studies of HTD1801 across several indications have been mild to moderate gastrointestinal (GI) AEs, primarily diarrhea and nausea. The purpose of this post-hoc analysis was to characterize the time course and severity of GI AEs in patients with MASH and T2DM treated with HTD1801 for 18 weeks. Diarrhea and nausea, the most commonly occurring of GI AEs, followed a trend that was consistent with all reported GI AEs; they showed early onset (within the first 4 weeks), were mild or moderate in severity, and importantly, showed a decreasing incidence and prevalence over the course of treatment. These data demonstrate that with continued treatment with HTD1801, GI tolerability improves supporting its potential for long-term use for the treatment of chronic disease, such as MASH.

About HighTide Therapeutics

HighTide Therapeutics, Inc. (HKEX: 2511) is a globally integrated biopharmaceutical company focusing on the discovery and development of first-in-class multifunctional multi-targeted therapies with chronic liver and metabolic diseases with significant unmet medical needs. The company is developing multiple clinical assets, including therapy for metabolic dysfunction-associated steatohepatitis (MASH), type 2 diabetes (T2DM), severe hypertriglyceridemia (SHTG), primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC). Berberine ursodeoxycholate (HTD1801), the company’s lead drug candidate, received Fast Track designation from the U.S. FDA for both NASH and PSC, as well as Orphan Drug designation for PSC. In China, HTD1801 has been included in the National Major New Drug Innovation Program under the 13th Five-Year Plan for Major Technology Project.

Disclaimer

The information contained herein is based solely on events or data available as of the date of this document. Unless required by law, we are under no obligation to update or publicly revise any forward-looking statements or events beyond those anticipated, even if new information, future events, or other circumstances arise after the date of the forward-looking statement. Please review this document carefully and be aware that our actual future performance or results may significantly deviate from expectations. All statements in this document are made as of the publication date and may change considering future developments.

For more information, please visit www.hightidetx.com.

Contact: pr@hightidetx.com 



Copyright 2024 ACN Newswire. All rights reserved. http://www.acnnewswire.com

New Research Launched at BIO24 Finds CROs with In-house Regulatory Affairs Deliver 30% Savings, Halve Timelines and Cut Risk for Biotechs

WAKE FOREST, N.C. | ADELAIDE, AUS, June 4, 2024 – (ACN Newswire) – Avance Clinical, the award-winning Australian and North American market-leading CRO for biotechs, is sharing new data at BIO 2024 from Frost & Sullivan research showing biotechs save more than 30% in costs and halve start-up times with CROs that have in-house scientific and regulatory affairs.

Meet the team at BIO 2024 Booth #5601

DOWNLOAD THE REPORT HERE

According to the report key benefits for biotechs with CROs that have in-house scientific and regulatory affairs included:

  • Decrease trial startup timelines by up to 50% by supporting sponsors in preparing the study protocols, reviewing essential documents and prepping site for activation. 
  • Reduced compliance risk and achieve zero errors by preparing necessary regulatory documents, compile submission dossiers and manage responses with regulatory authorities 
  • Decreased cost to sponsors by up to 30% by enabling sponsors to leverage benefits of full-service CRO services and avoiding standalone contracts with independent regulatory affairs agency. 

Avance Clinical’s Chief Scientific Officer Gabriel Kremmidiotis said some of the biotech services offered by the Avance Clinical in-house Scientific and Regulatory Affairs team included:

  • Regulatory Strategy Development: We devise regulatory strategies to navigate diverse regulatory landscapes, ensuring timely submissions and approvals. 
  • Liaison with Regulatory Authorities: We serve as the primary liaison between our clients and regulatory authorities, maintaining open lines of communication and addressing inquiries promptly.
  • Surrogate Development: Acting as a surrogate development department, we assist start-up companies in demonstrating safety and preliminary clinical proof of concept of their assets.
  • Streamlined Marketing Application: Our medium-term aim is to offer a streamlined and flexible marketing application experience to our clients through our fully integrated functions within SRMA, harnessing our comprehensive global expertise.
  • Adherence to GCP Standards: We utilize quality systems that uphold adherence to Good Clinical Practice (GCP) standards, safeguarding the integrity and ethical conduct of clinical trials. 

Avance Clinical recent news:

Avance Clinical is focussed on accelerating drug development for its biotech clients, from preclinical stages through to later phase trials.

Avance Clinical CEO, Yvonne Lungershausen said “It’s clear there is a demand for a mid-sized, agile, and responsive CRO with an in-house regulatory affairs team, and a proven track record of swiftly advancing high-quality clinical programs”.

“Our Australian and New Zealand operations have been delivering successful early phase clinical trials for decades, while our European and North American operations as well as our new Asia operations makes us an ideal CRO partner for later phase biotechs that are seeking access to significant patient populations,” she said.

“Our global teams offer our biotech clients world-class quality data and seamless geographic expansions to accelerate their drug development programs and position for success.” 

“Avance Clinical’s study data is accepted by all the main regulatory authorities including the EMA and FDA.” 

“Biotechs are looking for a partner that can start fast with high-quality data that is readily accepted by the US FDA and other regulatory agencies. Backed by our in-house global regulatory affairs team, we can navigate biotechs through regulatory complexities with confidence including FDA, EMA, MFDS and TGA submissions,” she said.

“In addition, our GlobalReady Site Partnership Network of over 2,500 highly qualified sites across the globe ensures maximum efficiency and effectiveness for our biotech clients’ trials.”

Lungershausen said this is our GlobalReady program and we currently have more than 90 biotech clients leveraging this unique, streamlined multi-phase and multi-region process. “With a globalized strategy, we ensure efficiency every step of the way,” she said.

DOWNLOAD THE REPORT HERE

Find out more:

  • Learn about the GlobalReady model
  • For more information about the benefits of running your next study with Avance Clinical contact us
  • Request a Proposal here

Media Contact:
Avance Clinical
media@avancecro.com 
Kate Thompson

About Avance Clinical

Avance Clinical is the largest premium full-service Australian and North American CRO delivering quality clinical trials, with globally accepted data, in Australia, New Zealand and the US for international biotechs. The company’s clients are biotechs completing Phase I to Phase III of their drug development program that requires fast, agile, and adaptive solution-oriented clinical research services.

Frost & Sullivan Awards
Avance Clinical, a Frost & Sullivan Asia-Pacific CRO Market Leadership Award recipient for the past four years, has been providing CRO services in the region for more than 26 years.

Pre-clinical through to mid to late phase
Avance Clinical offers pre-clinical services with their experienced ClinicReady team right from pre-clinical through to Phase III clinical services leveraging significant Australian Government incentive rebates of up to 43.5% and rapid start-up regulatory processes.

With experience across more than 120 indications, the CRO can deliver world-class results and high-quality internationally accepted data for FDA and EMA review.

Technology
Avance Clinical uses state-of-the-art technology and gold standard systems across all functional areas to provide clients with the most effective processes. Medidata, Oracle, TrialHub, Certinia, Salesforce, Zelta and Medrio are just some of the technology partners.

www.avancecro.com



Copyright 2024 ACN Newswire. All rights reserved. http://www.acnnewswire.com

[MEDIA ALERT] Fast Food Era – Is This The Demise of A Good Digestive Health?

SINGAPORE, June 3, 2024 – (ACN Newswire) – The fast-paced lifestyle of Singaporeans has led many to turn to fast food as a convenient dining choice. According to a 2018 Nielsen survey, it is revealed that 76% of Singaporeans choose fast food outlets for a speedy meal. In addition, about 55% of Singaporeans prefer to eat out on a weekly basis instead of home-cooked meals. Experts believe that the main appeal of fast food largely stems from the demands of their busy schedules and lifestyle changes apart from its affordability and convenience. 

However, the increased consumption of fast food and takeaways has also led to a rise in digestive health issues among the population. In 2022, the global Digestives & Intestinal Remedies market reached US$18.79 billion, and the market is projected to reach a CAGR of around 2% by 2024. 

To mark World Digestive Health Day on 29 May, LAC is dedicated to raise awareness of digestive health challenges faced by Singaporeans. Recognising the impact of dietary habits and lifestyle changes on digestive health, LAC offers targeted solutions aimed at supporting and optimising digestive functions, promoting better overall gut health. 

With over 25 Billion CFUs of active probiotics and 12 strains of friendly bacteria, LAC Probiotic Complex 25 Billion CFU – Daily Support effectively maintains probiotic levels and boosts a healthy digestive system; promoting a balanced microbiome. In addition, it counterbalances poor dietary choices caused by the overconsumption of fast food.

Digestive issues can arise when the body lacks sufficient enzymes to break down food effectively. LAC’s GastroRX® Digest – Enzymes offers a solution to this problem. This specialised formula contains a blend of enzymes that work together to enhance the digestion and absorption of nutrients from complex foods. This can lead to improved nutrient intake, reduced digestive discomfort, and good overall digestive health. 



Copyright 2024 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Avance Clinical Expands Specialist CNS, Cardiometabolic, and Rare Diseases CRO Services in Europe with Julius Clinical

WAKE FOREST, N.C. |  ADELAIDE, AUS, May 31, 2024 – (ACN Newswire) – Avance Clinical, the award-winning Australian and North American market-leading CRO for biotechs has signed a Memorandum of Understanding (MOU) with Julius Clinical, a leading CNS, cardiometabolic, and rare diseases specialist CRO with extensive site relationships in the region.

Meet the Avance Clinical team at BIO 2024 – Book a meeting now.

Julius Clinical, established in 2008 and headquartered in Zeist, The Netherlands, specializes in CNS, cardiometabolic, and rare diseases. The non-exclusive MOU between Avance Clinical and Julius Clinical offers a streamlined global solution for biotech clients.

Avance Clinical CEO, Yvonne Lungershausen noted that Avance Clinical has expanded globally establishing operations now in Europe, Australia, New Zealand, Asia and North America.

She emphasized, “Avance Clinical is now a global CRO for biotechs. In addition to our existing operations, our specialist partner CROs work alongside our teams to ensure our biotech clients benefit from the most experienced scientific, regulatory, and clinical operations teams across various therapeutic areas and regions”.

“Julius Clinical are an ideal partner for Avance Clinical because they lead with scientific expertise and can support our biotech clients with specialist CNS, cardiometabolic and rare diseases clinical operations and site relationships in Europe,” Lungershausen said.

She added, “Julius Clinical clients can also leverage Avance Clinical operations in Asia, Australia, New Zealand, and North America for their expanded later phase trials”.

Julius Clinical has supported over 380 clinical trials, enrolling more than 220,000 participants in around 39 countries.

Lungershausen said that Avance Clinical teams across Europe, Australia, New Zealand, Asia, and North America provide world-class data and facilitate seamless geographic expansions to accelerate drug development programs, with study data accepted by regulatory authorities including the EMA and FDA. 

Martijn Wallert, CEO of Julius Clinical, added, “We are excited to be partnering with Avance Clinical. Biotechs seek partners that can start quickly with high-quality data accepted by regulatory agencies like the MHRA, EMA, and US FDA. Together with Avance Clinical, we offer a nimble, flexible, and scientifically robust service, providing a tailored global solution”.

Avance Clinical is committed to accelerating drug development for biotech clients from early to later phase trials, allowing clients to remain with one CRO throughout their clinical development program. “This is our GlobalReady program, currently utilized by more than 90 biotech clients. Our globalized strategy ensures efficiency at every step,” Lungershausen concluded.

Find out more:

  • Learn about the GlobalReady model
  • For more information about the benefits of running your next study with Avance Clinical contact us
  • Request a Proposal here

Media Contact:
Avance Clinical
media@avancecro.com 
Kate Thompson

About Avance Clinical

Avance Clinical is the largest premium full-service Australian and North American CRO delivering quality clinical trials, with globally accepted data, in Australia, New Zealand and the US for international biotechs. The company’s clients are biotechs completing Phase I to Phase III of their drug development program that requires fast, agile, and adaptive solution-oriented clinical research services.

Frost & Sullivan Awards
Avance Clinical, a Frost & Sullivan Asia-Pacific CRO Market Leadership Award recipient for the past four years, has been providing CRO services in the region for more than 26 years.

Pre-clinical through to mid to late phase
Avance Clinical offers pre-clinical consulting and regulatory services with their experienced ClinicReady team right from pre-clinical through to Phase III clinical services leveraging significant Australian Government incentive rebates of up to 43.5% and rapid start-up regulatory processes.

With experience across more than 120 indications, the CRO can deliver world-class results and high-quality internationally accepted data for FDA and EMA review.

Technology
Avance Clinical uses state-of-the-art technology and gold standard systems across all functional areas to provide clients with the most effective processes. Medidata, Oracle, TrialHub, Certinia, Salesforce, Zelta and Medrio are just some of the technology partners.

www.avancecro.com

About Julius Clinical

Julius Clinical, founded in 2008 and based in Zeist, The Netherlands, is a scientifically focused CRO providing end-to-end clinical trial service to pharmaceutical and biotechnology customers, as well as governments and academia. Julius Clinical’s renowned scientific leaders are at the forefront of their fields, which combine with operational excellence and a global network of research sites to deliver tailor-made solution for customers and their clinical trials. With a focus on the therapeutic areas of CNS, cardio-metabolic, renal, and rare diseases, Julius Clinical has grown to approximately 200 employees and has supported over 380 clinical trials, enrolling more than 220,000 participants in around 39 countries.

www.juliusclinical.com 



Copyright 2024 ACN Newswire. All rights reserved. http://www.acnnewswire.com

BioMed X Institute and Boehringer Ingelheim Successfully Complete Schizophrenia Research Project

HEIDELBERG, Germany, May 28, 2024 – (ACN Newswire) – German independent research institute BioMed X announces the successful completion of its second neuroscience project in partnership with Boehringer Ingelheim in the field of psychiatric disorders. The data resulting from this project have been acquired by Boehringer Ingelheim, where this research will be continued, potentially paving the way for novel therapies.

This research project was launched in 2020 at the BioMed X Institute in Heidelberg and led by Dr. Ebru Ercan Herbst, now a professor at Reutlingen University, Germany. Her team has created both in vivo and in vitro platforms to study myelination of neurons and the development of oligodendrocytes – a subtype of glial cells – in the context of schizophrenia. Their novel in vitro platform for studying myelination was published last year in Cell Press – STAR Protocols (PMID: 36933222). Dr. Ercan Herbst’s team has also identified a relevant mouse model exhibiting the hypomyelination pathology associated with schizophrenia to be used for future research. In addition to the cell and mouse models, the BioMed X neuroscientists have analyzed the RNA expression of different human brain regions in post-mortem samples from schizophrenia patients and controls. Their soon-to-be-published findings reveal that there are differentially expressed genes and pathways in schizophrenia brains, particularly in oligodendrocytes, when compared to control brains, which could have significant implications for designing new therapies, not only for schizophrenia but also for other neurological disorders like major depressive disorder or bipolar disorder, which share a common hypomyelination pathology.

Dr. Christian Tidona, Managing Director & Founder of the BioMed X Institute: “This is already our second successfully completed project with Boehringer Ingelheim in the field of psychiatry. We are looking forward to continuing our successful collaboration with our ongoing research projects in brain sensor development in Heidelberg and in the field of wound healing and fibrosis at our new joint XSeed Labs on the U.S. campus of Boehringer Ingelheim in Ridgefield, CT.”

“Together with partners from across the global neuroscience community, we are constantly exploring new scientific avenues to address the huge unmet need of those living with mental health conditions,” Hugh Marston, Global Head CNS Discovery Research at Boehringer Ingelheim, stated. “The partnership with BioMed X and the fruitful collaboration with Dr. Ercan Herbst’s team has yielded exciting insights that will help us initiate projects to further progress our precision psychiatry approach to transform patients’ lives.”

About BioMed X

BioMed X is an independent research institute with sites in Heidelberg, Germany, New Haven, Connecticut, XSeed Labs in Ridgefield, Connecticut, and a worldwide network of partner locations. Together with our partners, we identify big biomedical research challenges and provide creative solutions by combining global crowdsourcing with local incubation of the world’s brightest early-career research talents. Each of the highly diverse research teams at BioMed X has access to state-of-the-art research infrastructure and is continuously guided by experienced mentors from academia and industry. At BioMed X, we combine the best of two worlds – academia and industry – and enable breakthrough innovation by making biomedical research more efficient, more agile, and more fun.

Contact Information

Flavia-Bianca Cristian
Recruiting & Communications Manager 
fbc@bio.mx
+49 6221 426 11 706

Swathi Lingam
Scientific Communication & Editorial Associate 
lingam@bio.mx
+49 6221 426 11 27

SOURCE: BioMed X Institute



Copyright 2024 ACN Newswire. All rights reserved. http://www.acnnewswire.com